Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study.
Fougerousse AC, Ghislain PD, Reguiai Z, Maccari F, Parier J, Bouilly Auvray D, Chaby G, Pallure V, Schmutz JL, Clément C, Jacobzone C, Begon E, Esteve E; GEM ResoPso. Fougerousse AC, et al. Among authors: ghislain pd. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e644-e646. doi: 10.1111/jdv.16511. Epub 2020 May 25. J Eur Acad Dermatol Venereol. 2020. PMID: 32314452 No abstract available.
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, Ghislain PD, Torres T, Ioannides D, Aassi M, Schulz B, Jagiello P; SERENA study group. Augustin M, et al. Among authors: ghislain pd. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1796-1804. doi: 10.1111/jdv.18329. Epub 2022 Jul 4. J Eur Acad Dermatol Venereol. 2022. PMID: 35696305
Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe.
de Graaf M, Janmohamed SR, Schuttelaar MLA, Agner T, Alfonso JH, De Schepper S, Deleuran M, Despontin K, Elenius V, Ghislain PD, Huilaja L, Johansson EK, Kvenshagen BK, Mandelin JM, Olset H, Svensson A, van Tuyll van Serooskerken AM, Thyssen JP, Vestergaard C. de Graaf M, et al. Among authors: ghislain pd. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2153-2165. doi: 10.1111/jdv.18410. Epub 2022 Jul 19. J Eur Acad Dermatol Venereol. 2022. PMID: 35793471 Free PMC article.
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H. Thaçi D, et al. Among authors: ghislain pd. Br J Dermatol. 2010 Aug;163(2):402-11. doi: 10.1111/j.1365-2133.2010.09791.x. Epub 2010 Apr 2. Br J Dermatol. 2010. PMID: 20377585 Clinical Trial.
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, Landells I, Hoeger PH, Unnebrink K, Seyger MMB, Williams DA, Rubant S, Philipp S. Thaçi D, et al. Among authors: ghislain pd. Br J Dermatol. 2019 Dec;181(6):1177-1189. doi: 10.1111/bjd.18029. Epub 2019 Jul 25. Br J Dermatol. 2019. PMID: 31017657 Free PMC article. Clinical Trial.
68 results